# A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

> **NCT06577194** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 35 (estimated)

## Conditions studied

- Rectal Cancer
- Advanced Solid Tumor

## Interventions

- **DRUG:** Sintilimab + IL-2 Combined with CAPOX
- **RADIATION:** Short-course radiotherapy

## Key facts

- **NCT ID:** NCT06577194
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-05
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-10-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06577194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06577194, "A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT06577194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*